Following stratification per patient factor, insulin-treated T2DM patients with underlying cardiovascular diseases (CVDs) were at a greater risk of developing genital infections when exposed to SGLT-2 inhibitors compared against metformin-receiving patients, with an adjusted OR (92% CI) was 2.29 (1.19–4.37). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.